Ibrutinib is an inhibitor of BTK kinase, which can covalently bind to the cysteine residues in the active center of BTK, thereby inhibiting the activity of B cells. Ibrutinib has a significant effect on B-cell lymphoma, and especially For a variety of patients with relapsed advanced lymphoma. What are the common adverse reactions of ibrutinib?

According to the physique of each person, the adverse reactions of ibrutinib in most patients are relatively mild. Mild adverse reactions mainly include: 

1. Bleeding: monitoring and management of bleeding. When severe anemia occurs, blood components can be infused appropriately. 

2. There are many gastrointestinal reactions: vomiting, nausea, diarrhea, etc. can occur, which are the most common side effects. If the patient has diarrhea, he can take orally Biqi or Imodium tablets as directed by the doctor. If necessary, intravenous nutritional support can be taken. In addition, if the patient has nausea and vomiting, he can eat light and easy to digest food, eat small amounts of meals, eat less sweets and gas-producing foods, and give metoclopramide orally according to the doctor's instructions. 

3. Hypertension: monitor blood pressure when taking drugs. When hypertension is severe, take sartan and pril antihypertensive drugs. In addition, there are some serious adverse reactions of ibrutinib.

There are still many serious adverse reactions to anti-tumor drugs. At present, there are two main serious adverse reactions of ibrutinib, both of which may threaten the lives of our patients. The first is the second primary malignant tumor: for patients with other malignant tumors, including skin cancer and other cancers. Corresponding anti-tumor treatment should be given urgently. The second is Tumor Lysis Syndrome (TLS): assess baseline risk and take preventive measures. Monitor and process TLS, correct electrolyte acid-base balance disorder. During our treatment, we must see a doctor regularly for review, and we must not ignore some of the changes that have occurred in our body.